MGI announced today that it has received market clearance for its G and T Series sequencers in Asia Pacific countries and Europe.
Its DNBSEQ-T7, DNBSEQ-G400, and DNBSEQ-G50 sequencers are now cleared in European countries, recognized with the CE-IVD mark and ready for deployment in clinical settings. The European IVD CE Mark approval opens a wider global market with growing potential in clinical applications and enables MGI to support more large-scale population sequencing projects, particularly with the DNBSEQ-T7.
With its powerful processing capabilities, the DNBSEQ-T7 delivers the highest daily data output of any DNA sequencer, sequencing up to 60 human genomes per day. Designed for clinical and large-scale applications, it supports population genomic health projects with Whole Genome Sequencing (WGS), clinical research with Whole Exome Sequencing (WES), and more. MGI’s G Series sequencers (DNBSEQ-G400 and DNBSEQ-G50) are benchtop sequencers offering unique flexibility and adaptability across a variety of applications.
In the APAC market, MGI G Series sequencers, including the DNBSEQ-G400 and G50, have received regulatory approvals in China, Japan, Australia, Singapore, Malaysia, Thailand, and Vietnam.
“Regulatory clearance for MGI’s G and T Series sequencers is a major milestone for our company,” said Mu Feng, MGI’s Chief Executive Officer. “MGI can accelerate sequencing projects of any scale and deliver high-quality data with the most adaptable, capable, and efficient sequencers available. It also confirms that our sequencers meet the highest standards for clinical use.”
